Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors
2009
Starting from quinazoline 3a, we designed potent and selective ALK5 inhibitors over p38MAP kinase from a rational drug design approach based on co-crystal structures in the human ALK5 kinase domain. The quinazoline 3d exhibited also in vivo activity in an acute rat model of DMN-induced liver fibrosis when administered orally at 5 mg/kg (bid).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
17
References
62
Citations
NaN
KQI